Kiromic BioPharma (Kiromic BioPharma) Debt-to-Asset : 1.08 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Debt-to-Asset?

Kiromic BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $12.83 Mil. Kiromic BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.75 Mil. Kiromic BioPharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $12.63 Mil. Kiromic BioPharma's debt to asset for the quarter that ended in Mar. 2024 was 1.08.

Kiromic BioPharma Debt-to-Asset Historical Data

The historical data trend for Kiromic BioPharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Debt-to-Asset Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.02

0.79

1.28

Kiromic BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.91	0.74	0.80	1.28	1.08

Competitive Comparison of Kiromic BioPharma's Debt-to-Asset

For the Biotechnology subindustry, Kiromic BioPharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiromic BioPharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Debt-to-Asset falls into.

Kiromic BioPharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kiromic BioPharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(14.631	+	0.912)	/	12.169
	=	1.28

Kiromic BioPharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.834	+	0.747)	/	12.628
	=	1.08

Kiromic BioPharma (OTCPK:KRBP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Kiromic BioPharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiromic BioPharma (Kiromic BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Executives

Brian Hungerford	officer: CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark	officer: Interim CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva	director, officer: Chairman, CEO, and President	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan	officer: Chief Technology Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez	officer: See Remarks	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider	director	ONE VISION DRIVE, NATICK MA 01760
Michael Nagel	director	C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani	director	C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck	officer: Chief Medical Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino	director, officer: CSIO	7707 FANNIN, SUITE 140, HOUSTON TX 77054